Loading...
•
Sep 30, 2024
Tarsus Q3 2024 Earnings Report
Tarsus' Q3 2024 earnings were released, highlighted by XDEMVY net product sales and strengthened payer coverage.
Key Takeaways
Tarsus Pharmaceuticals reported a successful third quarter, marked by significant growth in XDEMVY net product sales, driven by increased patient reach and strong payer coverage. The company also presented new clinical data and expanded its leadership team.
Generated $48.1 million in XDEMVY net product sales, an approximately 18% increase over Q2 2024.
Delivered more than 41,400 bottles of XDEMVY to patients.
Secured broad commercial and Medicare reimbursement for XDEMVY, now covering more than 80% of covered lives.
Completed recruitment and deployment of approximately 50 new sales force representatives and leaders.
Tarsus
Tarsus
Forward Guidance
Tarsus expects to close the year with another strong quarter, reflecting the benefits of an expanded sales force and direct-to-consumer TV campaign.